> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Court Backs Vascepa ANDAs
- URL: https://www.fdaweb.com/court-backs-vascepa-andas/
- Published: 2020-03-31T12:00:00.000Z
- Updated: 2026-09-14T16:09:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146461

Nevada’s federal court has ruled that six Amarin patents on its Vascepa (icosapent ethyl) heart drug are “obvious” and thus invalid, clearing the way for two generic companies to continue to pursue their ANDAs. *Reuters* [reports](https://www.reuters.com/article/us-amarin-stocks/amarin-loses-patent-lawsuit-on-main-drug-shares-tumble-idUSKBN21I1XR?feedType=RSS&feedName=healthNews&ref=fdaweb.com) that Amarin said it will try to prevent the launch of a generic version of the drug by seeking a preliminary injunction if FDA approves an ANDA.

ANDAs are pending from Hikma Pharmaceuticals and Dr.Reddy’s Laboratories.

Hikma [said](https://www.prnewswire.com/news-releases/hikma-confirms-favourable-ruling-in-generic-vascepa-patent-suit-301032237.html?ref=fdaweb.com) it is considering its options for a product launch following FDA approval, including the potential for an at-risk launch if the Nevada court decision is appealed by Amarin.

Vascepa was first approved in 2012 to lower high triglycerides and recently received approval for expanded heart benefit claims.